Skip to main content
. 2012 Oct 21;18(39):5570–5575. doi: 10.3748/wjg.v18.i39.5570

Table 4.

Pretreatment clinical and virological characteristics between hepatitis B virus DNA-negative and -positive group at year 2 during entecavir therapy

Characteristics HBV DNA-negative group HBV DNA-positive group P value
(n = 19) (n = 31) Univariate analysis Multivariate analysis
Age 51 (31-73) 52 (32-80) NS
Gender (male:female) 12:7 20:11 NS
Disease (CH:LC/HCC) 17:2 27:4 NS
ALT (IU/L) 36 (12-366) 108 (13-602)   0.03 NS
Platelet counts (× 104/mL) 19.0 (8.8-35.1) 17.8 (3.4-26.8) NS
Albumin (mg/dL) 4.35 (3.84-4.85) 4.14 (2.28-4.72) NS
HBV genotype (B:C:others) 0:19:0 0:31: NS
HBeAg status (positive:negative) 3:16 21:10 < 0.01 NS
HBV DNA (log copies/mL) 5.1 (3.1-7.4) 7.6 (3.7-8.8) < 0.01 NS
qHBsAg level (log IU/mL) 3.31 (1.90-4.08) 4.20 (3.06-4.87) < 0.01 0.03
HBcrAg level (log U/mL) 3.45 (3.0-> 6.8)  > 6.8 (3.0-> 6.8) NS
Pre-C mutation (%) 75.0 43.3 NS
Core promoter mutation (%) 37.5 60.0 NS

CH: Chronic hepatitis; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; qHBsAg: Quantitation of hepatitis B surface antigen level; HBcrAg: HBV core-related antigen; NS: Not significant.